Exelixis Inc. (EXEL) (Co-lead) 3/10 $11 $4.74 $189.75 -57% InterMune Inc. (ITMN) (Co-lead) 9/14 $24 $12.60 $96 -48% Jefferies & Co...InterMune Inc. (ITMN) 9/14 $24 $12.60 $96 -48% NeoStem Inc. (AMEX:NBS) (Co-lead) 7/18 $1.20 $0.51 $16.5 -58% Optimer Pharmaceuticals Inc. (OPTR) 2/11 $11.25 $12.24 $67.5 +9% Raptor Pharmaceutical Corp. (RPTP) (Lead) 9/13 $4 $6.26 $46 +57% Threshold Pharmaceuticals Inc. (THLD; Co-lead) 3/11 $2.10 $1.48 $30 -30% J.P. Morgan Securities Ariad Pharmaceuticals Inc. (ARIA

InterMune Inc. (Brisbane, Calif.) Esbriet Pirfenidone Idiopathic pulmonary fibrosis The private Institute for Quality and Efficiency in Health Care in Germany determined that there is no additional benefit to Esbriet

Roche has been testing combinations of Pharmasset-partnered candidate RG7128 with danoprevir, a protease inhibitor originally developed at Brisbane, Calif.-based InterMune Inc

InterMune Inc., of Brisbane, Calif., reported preliminary fourth-quarter net sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) totaling about $2.8 million

January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Company Company Type/Product Area Terms/Details Amarantus BioScience Inc. Power3 Medical Products Inc. Deal to buy all of the intellectual property assets from Power3, giving Amarantus the ability to acquire IP for the diagnosis of multiple neurodegenerative diseases and oncology Amarantus is paying $40,000, and the deal includes five patents and 20

InterMune Inc., of Brisbane, Calif., said the private Institute for Quality and Efficiency in Health Care (IQWiG) in Germany determined that there is no additional benefit to idiopathic pulmonary fibrosis drug Esbriet (pirfenidone

InterMune Inc., of Brisbane, Calif., appointed Angus C. Russell to its board

Besides Pharmasset, there is Roche AG, which has been testing combinations of Pharmasset-partnered candidate RG7128 with danoprevir, a protease inhibitor originally developed at Brisbane, Calif.-based InterMune Inc

The Swiss big pharma has been testing combinations of RG7128, an HCV cytosine nucleoside polymerase inhibitor partnered with Princeton, N.J.-based Pharmasset Inc., and danoprevir (RG7227), a protease inhibitor it gained from Brisbane, Calif.-based InterMune Inc

The biggest, however, was not specialty pharma, but InterMune Inc.'s $231 million stock and convertible note raises to fund the European launch of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone). (See BioWorld Today, Sept. 15, 2011.) Public companies raised an additional $833.3 million in the third quarter through private placements, registered direct offerings, royalty monetization, at-the-market deals, loans and other such financing alternatives

The biggest, however, was not specialty pharma, but InterMune Inc.'s $231 million stock and convertible note raises to fund the European launch of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone). (See BioWorld Today, Sept. 15, 2011.) Public companies raised an additional $833.3 million in the third quarter through private placements, registered direct offerings, royalty monetization, at-the-market deals, loans and other such financing alternatives

InterMune Inc. (Brisbane, Calif.) Esbriet Pirfenidone Idiopathic pulmonary fibrosis Data supported the longer-term safety and tolerability of Esbriet (9/27) Mundipharma International Inc. (Cambridge, UK) Flutiform A combination of fluticasone propionate, an inhaled corticosteroid and long-acting beta2-agnist formoterol fumarate Asthma Phase III data showed it improved lung function and effectively controlled symptoms across different asthma severities in adolescents and adults

Shares/Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post-OfferingMarketCap (M)% FOLLOW-ON OFFERINGS InterMune Inc. (Brisbane, Calif.; ITMN)1 9/14/11 9/14/11 Conver-tible senior notes

InterMune Inc., of Brisbane, Calif., presented data supporting the longer-term safety and tolerability of Esbriet (pirfenidone) in patients with idiopathic pulmonary fibrosis

Based on those factors, he predicted that successful upcoming biotech launches might include BioMarin Pharmaceutical Inc.'s GALNS (N-acetylgalactosamine 6-sulfatase) for mucopolysaccharidosis Type IVA, NPS Pharmaceuticals Inc.'s Gattex (teduglutide) for short bowel syndrome, Amylin Pharmaceuticals Inc.'s metreleptin for lipodystrophy, Vertex's VX-770 for cystic fibrosis, Biogen Idec Inc.'s BG-12 for multiple sclerosis, InterMune Inc.'s Esbriet (pirfenidone) for idiopathic pulmonary fibrosis

InterMune Inc

Managing Editor Set to make idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) available to patients in Germany Thursday, about six months after receiving European approval, InterMune Inc

Former InterMune Inc...InterMune Inc., of Brisbane, Calif., announced pricing for idiopathic pulmonary fibrosis drug Esbriet (pirfenidone), which is expected to launch in Germany later this week

InterMune Inc., of Brisbane, Calif., said it plans to offer 4 million shares of common stock and $100 million aggregate principal amount of convertible senior notes due 2018 in concurrent underwritten public offerings